To test whether inhibition of RIPK1 kinase activity also enhances tumor responses to ICB therapy, we treated B16F10 xenograft tumors with the RIPK1 kinase inhibitor T2I, alone or in combination with anti-PD1. Here, RIPK1 is linked to neoplasm.